Updates

ARROW GREENTECH LTD August 26, 2026 Manager (CRD) Manager (CRD) BSE Limited National Stock Exchange of India Ltd. (NSE) P.J. Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex Mumbai 400 001 Bandra (E), Mumbai - 400051 Ref: Script Code- 516064 Script Code- ARROWGREEN Dear Sir/Madam, Sub: Annual Report of the Company for the financial year 2025-26 Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), please find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26 including the Notice of Thirty Fourth (34th) Annual General Meeting of the Company scheduled to be held on Friday, September 18, 2026 at 3:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The Annual Report including the Notice of AGM is being sent through electronic mode to all those Members whose e-mail address(es) are registered with the Company or Registrar and Share Transfer Agents (RTA) of the Company or respective Depository Participants (DPs). Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, a letter providing the web-link, including the exact path, where complete details of the Annual Report 2025-26 including Notice of AGM are available on Company’s website, is being sent to those Members who have not registered their e-mail address(es) with the Company/RTA/DPs. Thanking you, Yours faithfully, For Arrow Greentech Limited Company Secretary ARROW GREENTECH LTD CIN No.: L21010MH1992PLC069281 Registered Office: 1/F Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai 400 053, Maharashtra, Phone: +91 22-4974 3758 , Email : contact@arrowgreentech.com Website: www.arrowgreentech com Works: Plot No 531 0,5311, GIDC, Ankleshwar 392002, Gujarat, INDIA Phone : +912646-224743/224744 E-mail : ank@arrowgreentech.com Contents CORPORATE BRIEF AND STATUTORY REPORTS Turnover (Rs. in Millions) 3,000 Chairman Message 2,486 2,500 2,060 2,090 Board of Directors 2,000 1,647 1,500 1,096 1,111 1,379 1,511 Corporate Information 1 1,000 354 Notice 2 500 309 Director's Report 16 2021-22 2022-23 2023-24 2024-25 2025-26 Standalone 309 1,096 1,379 2,060 1,647 Management Discussion & Analysis Report 38 Consolidated 354 1,111 1,511 2,486 2,090 Report on Corporate Governance 43 FINANCIAL STATEMENTS STANDALONE Profit after Tax (Rs. in Lacs) Independent Auditor's Report 59 7,000 6,190 6,301 6,000 4,739 Balance Sheet 68 5,000 4,249 4,000 3,930 2,933 3,000 1,888 1,226 Statement of Profit and Loss 69 2,000 1,000 Cash Flow Statement 70 (1,000) (171) (926) Statement of Changes in Equity 72 (2,000) 2021-22 2022-23 2023-24 2024-25 2025-26 Standalone (171) 1,888 3,930 6,190 4,249 Notes 73 Consolidated (926) 1,226 2,933 6,301 4,739 CONSOLIDATED Independent Auditor's Report 119 Balance Sheet 126 Earnings Per Share (Rs.) Statement of Profit and Loss 127 50.00 41.03 Cash Flow Statement 128 41.83 40.00 Statement of Changes in Equity 130 30.00 26.05 31.38 28.16 Notes 131 20.00 19.56 13.09 10.00 8.52 (1.21) (6.62) (10.00) 2021-22 2022-23 2023-24 2024-25 2025-26 Standalone (1.21) 13.09 26.05 41.03 28.16 Consolidated (6.62) 8.52 19.56 41.83 31.38 Chairman Message Dear Shareholders, and the Ministry of Commerce. Every patent we secure raises the entry As we close the financial year 2025–26, I write to you openly and with barrier for would-be competitors and confidence in the year ahead. After a record-setting FY25, this past year has converts scientific work into a durable, been one of consolidation rather than acceleration - a year in which our defensible asset. In an IP-led business, headline numbers moderated, even as the underlying franchise grew this moat is our single greatest source stronger, our innovation engine kept turning, and our balance sheet of long-term value, and it is deepening, remained as resilient as ever. I have always believed that the true measure year after year. We will continue to of a company is not in one year, but the consistency of its character across focus on developing proprietary the cycle. By that measure, Arrow Greentech has maintained itself with technologies with commercial discipline and evolved. applications across our businesses. FY25 was a strong year that set a high base. Viewed in that context, FY26 was a moderate year, even as the underlying fundamentals of the business Avery Pharmaceuticals: Building the Next Growth Vector remain firmly in place. Through Avery Pharmaceuticals, we continue to develop our capabilities in Performance Review: The Year in Numbers Novel Drug Delivery Systems, including mouth-dissolving and oral thin- For FY26, consolidated revenue stood at ` 2,005 million compared with film products. ` 2,434 million in FY25. Profit After Tax was ` 474 million against ` 630 million in the previous year, with a PAT margin of approximately 24%. In Avery has a portfolio of more than 54 approved nutraceutical and recognition of the company's continued strength and our confidence in the pharmaceutical products and also undertakes contract development and road ahead, the Board has recommended a dividend of `5 per share for the manufacturing. We remain focused on expanding customer relationships, year. securing repeat business and progressively developing opportunities in regulated pharmaceutical markets. Our balance sheet remains healthy, with adequate liquidity. This financial position enables us to continue investing in research and development, Global Presence: Gateways to the World capacity expansion and new business opportunities while maintaining a disciplined approach to capital allocation. Our subsidiaries in the United Kingdom and the Netherlands support our Green Segment: The Engine of Diversification engagement with customers and markets across Europe and other international regions. These entities provide a platform for business The clearest evidence of our strategy at work lies in our green portfolio. development, customer support and regulatory coordination as we seek to Revenue from our green products segment grew by an impressive 52 per expand our overseas presence. cent to ` 369 million in FY26 - a standout performance in an otherwise measured year. As India's largest manufacturer of water-soluble films, The Road Ahead: FY27 and Beyond marketed under our Watersol® brand, and with a widening basket of bio- compostable solutions, we are riding a structural and irreversible global As we enter FY27, I want to leave you with a sense of measured, grounded shift toward sustainable packaging and eco-friendly industrial materials. optimism. The variability of a single year does not define a franchise built on This is exactly the kind of steady, demand-led growth that complements our patents, proprietary technology and a fortress balance sheet - indeed, it is a broader portfolio, and it reflects the balanced, diversified strategy we have feature of the high-value model we have deliberately chosen, not a flaw deliberately pursued. Our leadership in this space was recognised within it. Our priorities are clear: to scale the green products business externally during the year, with our Water-Soluble Film technology winning through new capacity and applications; to convert our deep IP pipeline into the Commercial Innovation Award at the FIPSA Awards for Responsible the next generation of security solutions and related business verticals; to Packaging 2026. Our acquisition of land at the Dahej-II Industrial Estate grow Avery toward regulated markets through partnerships and approvals; positions us to scale this segment meaningfully in the years ahead. and to keep expanding our international footprint. High-Tech & Security Products: Normalisation & Continued Strength We remain steadfastly committed to the Hon. Prime Minister's vision of The High-Tech and Security products continue to be an important part of Make in India and Atma-Nirbhar Bharat and to the nation's self-reliance, our business. We manufactur [Showing first 8,000 characters — download PDF for full document]